Comparative Pharmacology
Head-to-head clinical analysis: ASTRAMORPH PF versus DILAUDID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASTRAMORPH PF versus DILAUDID.
ASTRAMORPH PF vs DILAUDID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mu-opioid receptor agonist; produces analgesia, sedation, and euphoria by mimicking endogenous endorphins.
Dilaudid (hydromorphone) is a full opioid agonist with high affinity for mu-opioid receptors, producing analgesia by mimicking endogenous endorphins and enkephalins. It also activates kappa and delta opioid receptors to a lesser extent.
Intravenous: 8-10 mg over 2-5 minutes; may be repeated every 8-12 hours as needed. Oral (immediate release): 10-20 mg every 4-6 hours as needed. Oral (extended release): 10-40 mg every 12 hours.
Initial: 2-4 mg orally every 4-6 hours as needed; or 1-2 mg intramuscularly, subcutaneously, or intravenously every 4-6 hours as needed.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours; prolonged in renal impairment (up to 12 hours in anuria) and elderly
2.5-3.5 hours (terminal); prolonged in hepatic/renal impairment
Renal: 70-80% unchanged; Biliary/Fecal: 10-20% as metabolites
Primarily renal (90% as hydromorphone-3-glucuronide and parent drug); <1% biliary/fecal
Category C
Category C
Opioid Analgesic
Opioid Analgesic